Digital Erasmus - a pan-European approach to teaching building performance and resilient design

The global COVID-19 pandemic in 2020 has forced universities to completely rethink their teaching concepts to provide safe, remote teaching of students off-campus. One of the challenges of this rapid transition is ensuring that the quality of the learning experience remains high and that students are able to engage and thrive in this new and predominantly digital environment. This project, entitled 'Digital Erasmus-a roadmap to using building performance simulation to achieve resilient design', responds to this context by seeking to transform the learning experience of students in built environment disciplines using a continuous digital learning cycle. This paper outlines the concept of the program and the learning objectives that it responds to, as well as some initial results highlighting the programs opportunity for students to work collaboratively and transnationally. The program is still in its infancy but it is hoped that it can serve as a template for similar future online courses that will promote safe, interdisciplinary and engaging collaboration amongst students from different universities

The Lantern Vol. 68, No. 1, Fall 2000

• In Attempting to Imitate J. Agard (III) • Headstones • Calligraphy Grace • Fifty Years • Morning • The Millstone • Quick Stop-Off • Jesus Wept (SuperBuick Bodybag) • Just a God • Amy • Silver Doubloons • Ogbanje • Left Behind • Asymmetrical Smile • Sundays • Pie in the Sky • No Surprises • Bill Gooden\u27s Son • Downcast Eyes Meet Tablecloth • Wetlands • Desperate Actions • Receiving End • A Pack of Matches • Coffeehttps://digitalcommons.ursinus.edu/lantern/1157/thumbnail.jp

The Lantern Vol. 68, No. 1, Fall 2000

• In Attempting to Imitate J. Agard (III) • Headstones • Calligraphy Grace • Fifty Years • Morning • The Millstone • Quick Stop-Off • Jesus Wept (SuperBuick Bodybag) • Just a God • Amy • Silver Doubloons • Ogbanje • Left Behind • Asymmetrical Smile • Sundays • Pie in the Sky • No Surprises • Bill Gooden\u27s Son • Downcast Eyes Meet Tablecloth • Wetlands • Desperate Actions • Receiving End • A Pack of Matches • Coffeehttps://digitalcommons.ursinus.edu/lantern/1157/thumbnail.jp

Why media representations of corporations matter for public health policy : a scoping review

BACKGROUND: Media representations play a crucial role in informing public and policy opinions about the causes of, and solutions to, ill-health. This paper reviews studies analysing media coverage of non-communicable disease (NCD) debates, focusing on how the industries marketing commodities that increase NCD risk are represented. METHODS: A scoping review identified 61 studies providing information on media representations of NCD risks, NCD policies and tobacco, alcohol, processed food and soft drinks industries. The data were narratively synthesized to describe the sample, media depictions of industries, and corporate and public health attempts to frame the media debates. RESULTS: The findings indicate that: (i) the limited research that has been undertaken is dominated by a focus on tobacco; (ii) comparative research across industries/risk-factors is particularly lacking; and (iii) coverage tends to be dominated by two contrasting frames and focuses either on individual responsibilities ('market justice' frames, often promoted by commercial stakeholders) or on the need for population-level interventions ('social justice' frames, frequently advanced by public health advocates). CONCLUSIONS: Establishing the underlying frameworks is crucial for the analysis of media representation of corporations, as they reflect the strategies that respective actors use to influence public health debates and decision making. The potential utility of media research lies in the insights that it can provide for public health policy advocates about successful framing of public health messages and strategies to counter frames that undermine public health goals. A better understanding of current media debates is of paramount importance to improving global health

Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension.

PURPOSE: This study assessed the uptake of the CONsolidated Standards of Reporting Trials (CONSORT)-Patient-Reported Outcomes (PRO) statement; determined if use of CONSORT-PRO was associated with more complete reporting of PRO endpoints in randomised controlled trials (RCTs) and identified the extent to which high-impact journals publishing RCTs with PRO endpoints endorse CONSORT-PRO. METHODS: CONSORT-PRO citations were identified by systematically searching Medline, EMBASE and Google from 2013 (year CONSORT-PRO released) to 17 December 2015. RCTs that cited CONSORT-PRO (cases) were compared to a comparable control sample of RCTs in terms of adherence to CONSORT-PRO using t tests. General linear models assessed the relationship between CONSORT-PRO score and key, pre-specified variables. The 100 highest-impact journals that published RCTs with PRO endpoints (2014-2015) were identified via a systematic Medline search. Instructions for authors were reviewed to determine whether journals endorsed CONSORT-PRO. RESULTS: Total CONSORT-PRO scores ranged from 47 to 100% for cases and 25-96% for controls. Cases had significantly higher total CONSORT-PRO scores compared to controls: t = 2.64, p = 0.01. 'Citing CONSORT-PRO', 'journal endorsing CONSORT-PRO' and 'dedicated PRO paper' were significant predictors of higher CONSORT-PRO adherence score: R (2) = 0.48, p < 0.001. 11/100 top-ranked journals endorsed CONSORT-PRO in their instructions to authors, seven of these journals published RCTs included as cases in this study. CONCLUSION: This study demonstrated improved PRO reporting associated with journal endorsement and author use of the CONSORT-PRO extension. Despite growing awareness, more work is needed to promote appropriate use of CONSORT-PRO to improve completeness of reporting; in particular, stronger journal endorsement of CONSORT-PRO

Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation

Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled “Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation” on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice